These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39028785)

  • 21. A patient responding to combined therapy with pirmenol and midodrine for refractory neurally mediated syncope complicated by prostatic hypertrophy.
    Mizuguchi Y; Ishimoto T; Kageyama N; Oishi Y; Emi S; Nagase N; Oki T
    Cardiovasc Drugs Ther; 2004 Sep; 18(5):405-8. PubMed ID: 15717144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent syncope in a 31-year-old army staff sergeant.
    Wiley TM; Luu VD
    Mil Med; 2002 Mar; 167(3):263-5. PubMed ID: 11901579
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
    Aminorroaya A; Tavolinejad H; Sadeghian S; Jalali A; Alaeddini F; Emkanjoo Z; Mollazadeh R; Bozorgi A; Oraii S; Kiarsi M; Shahabi J; Akbarzadeh MA; Rahimi B; Joharimoghadam A; Mohsenizade A; Mohammadi R; Oraii A; Ariannejad H; Apakuppakul S; Ngarmukos T; Tajdini M
    Am Heart J; 2021 Jul; 237():5-12. PubMed ID: 33689731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Successful midodrin treatment for vasovagal syncopes accompanied by asystole].
    Pevzner AV; Kuchinskaia EA; Vershuta EV; Al'bitskaia KV; Kheĭmetz GI; Tripoten' MI; Rogoza AN; Golitsyn SP
    Klin Med (Mosk); 2004; 82(9):53-6. PubMed ID: 15540425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of midodrin treatment of vasovagal syncope].
    Kuchinskaia EA; Pevzner AV; Vershuta EV; Al'bitskaia KV; Kheĭmets GI; Rogoza AN; Golitsyn SP
    Ter Arkh; 2004; 76(8):38-41. PubMed ID: 15471395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Midodrine: a role in the management of neurocardiogenic syncope.
    Ward CR; Gray JC; Gilroy JJ; Kenny RA
    Heart; 1998 Jan; 79(1):45-9. PubMed ID: 9505918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy.
    Sra J; Maglio C; Biehl M; Dhala A; Blanck Z; Deshpande S; Jazayeri MR; Akhtar M
    J Cardiovasc Electrophysiol; 1997 Jan; 8(1):42-6. PubMed ID: 9116967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based treatment for vasovagal syncope.
    Kuriachan V; Sheldon RS; Platonov M
    Heart Rhythm; 2008 Nov; 5(11):1609-14. PubMed ID: 18984541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum uric acid predicts therapeutic response to midodrine hydrochloride in children with vasovagal syncope: a pilot study.
    Du X; Li X; Zhang C; Liu P; Wang Y; Zhang Q; Du J; Liao Y; Jin H
    Eur J Pediatr; 2024 Jan; 183(1):371-378. PubMed ID: 37904034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What can I do when first-line measures are not enough for vasovagal syncope?
    Hutt Centeno E; Mayuga KA
    Cleve Clin J Med; 2018 Dec; 85(12):920-922. PubMed ID: 30526751
    [No Abstract]   [Full Text] [Related]  

  • 31. Vasovagal syncope: an update on the latest pharmacological therapies.
    Schleifer JW; Shen WK
    Expert Opin Pharmacother; 2015 Mar; 16(4):501-13. PubMed ID: 25534874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
    Behnoush AH; Yazdani K; Khalaji A; Tavolinejad H; Aminorroaya A; Jalali A; Tajdini M
    Heart Rhythm; 2023 Mar; 20(3):448-460. PubMed ID: 36509319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncope.
    Gracie J; Newton JL; Norton M; Baker C; Freeston M
    Europace; 2006 Aug; 8(8):636-43. PubMed ID: 16864617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. alpha-Adrenoceptor agonists for the treatment of vasovagal syncope: a meta-analysis of worldwide published data.
    Liao Y; Li X; Zhang Y; Chen S; Tang C; Du J
    Acta Paediatr; 2009 Jul; 98(7):1194-200. PubMed ID: 19397534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishing the Efficacy of Midodrine to Prevent Vasovagal Syncope.
    Brignole M
    Ann Intern Med; 2021 Oct; 174(10):1460-1461. PubMed ID: 34339220
    [No Abstract]   [Full Text] [Related]  

  • 36. Strategy for the management of vasovagal syncope.
    Bloomfield DM
    Drugs Aging; 2002; 19(3):179-202. PubMed ID: 12027777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary observations on the use of midodrine hydrochloride in the treatment of refractory neurocardiogenic syncope.
    Grubb BP; Karas B; Kosinski D; Boehm K
    J Interv Card Electrophysiol; 1999 Jul; 3(2):139-43. PubMed ID: 10387140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurocardiogenic syncope: latest pharmacological therapies.
    Chen LY; Shen WK
    Expert Opin Pharmacother; 2006 Jun; 7(9):1151-62. PubMed ID: 16732702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Summary for Patients: Midodrine to Prevent Fainting.
    Ann Intern Med; 2021 Oct; 174(10):I28. PubMed ID: 34339224
    [No Abstract]   [Full Text] [Related]  

  • 40. A patient treated with tilt training and midodrine after 68 seconds asystole during head-up tilt table testing.
    Oz F; Cizgici Y; Bilge AK
    Acta Cardiol; 2011 Aug; 66(4):523-5. PubMed ID: 21894812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.